
Enlasia Pharmaceuticals Private Limited
About Enlasia Pharmaceuticals Private Limited
Data last updated:
Enlasia Pharmaceuticals Private Limited was a private limited company based in Gurugram, Haryana, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the specialised services segment of the trading and commerce sector. It was incorporated on 30 July 2018.
The company was registered with the Registrar of Companies (ROC), Delhi, under CIN U51909HR2018PTC075143. Its GSTIN is 06AAFCE1278E1ZV (Haryana).
The company had an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It was led by directors Rakesh Mittal and Chhaya Bhatnagar.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office was at Office No. 581/17 Nai Basti Gurugram, Haryana, India – 122001.
As per the financials filed for FY 2023, the company reported a revenue of ₹1.71 Lakh, a growth of 139% compared to the previous year. For the same year it recorded a net profit of ₹96,165 (net margin 56.1%) and EBITDA of ₹96,165 (EBITDA margin 56.1%). Revenue has grown at a compounded annual rate (CAGR) of 67% over three years.
Company details
Contact details
Enlasia Pharmaceuticals Private Limited's registered office is in Gurugram, Haryana. Its e-mail address is in the company report.
- Email
- Registered AddressOffice No. 581/17 Nai Basti Gurugram, Haryana, India – 122001
- IndustryTrading, Specialty, Wholesale
To see the full contact details of Enlasia Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Enlasia Pharmaceuticals Private Limited
FY 2024 filings availableEnlasia Pharmaceuticals Private Limited reported revenue of ₹1.71 Lakh (up 139% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 67% over three years, including 139% growth in the latest year. EBITDA rose 420% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹96,165 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹96,165 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 56.1% | ||||
| Net Profit Margin | 56.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Enlasia Pharmaceuticals Private Limited, buy the company report.
Board of directors of Enlasia Pharmaceuticals Private Limited
Enlasia Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rakesh Mittal | Director | 30 Jul 2018 | 8 Years 3 Months | As last reported |
| Chhaya Bhatnagar | Director | 30 Jul 2018 | 8 Years 3 Months | As last reported |
Peer comparison
Enlasia Pharmaceuticals Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Omkam Pharmaceuticals Private Limited | ₹1.75 Lakh (FY 2025) | -26.0% | New Delhi, Delhi, India | |||
| Kokban Ayurvedic Pharmaceuticals Private Limited | ₹1.74 Lakh (FY 2018) | 7.0% | Mumbai, Maharashtra, India | |||
| Ocecure Pharmaceuticals Private Limited | ₹1.74 Lakh (FY 2022) | -51.0% | East Mumbai, Maharashtra, India | |||
| Cipa Pharmaceuticals Private Limited | ₹1.73 Lakh (FY 2025) | -38.0% | Udaipur, Rajasthan, India | |||
| Logyesthesia Pharmaceuticals Private Limited | ₹1.72 Lakh (FY 2016) | Nanded, Maharashtra, India | ||||
| Enlasia Pharmaceuticals Private Limitedthis company | ₹1.71 Lakh (FY 2023) | ₹96,165 | 56.1% | 139.0% | Gurugram, Haryana, India | |
| Alphonce Pharmaceuticals Private Limited | ₹1.71 Lakh (FY 2023) | Patna, Bihar, India | ||||
| T.C.L. Pharmaceuticals Limited | ₹1.71 Lakh (FY 2025) | Jaipur, Rajasthan, India | ||||
| Rivoma Pharmaceuticals Private Limited | ₹1.7 Lakh (FY 2025) | -62.0% | Chandrapur, Maharashtra, India | |||
| Doctor Choice Pharmaceuticals Private Limited | ₹1.69 Lakh (FY 2025) | -58.0% | Faridabad, Haryana, India | |||
| Raquel Pharmaceuticals Private Limited | ₹1.69 Lakh (FY 2020) | -88.0% | Vadodara, Gujarat, India |
To see the full peer comparison of Enlasia Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Enlasia Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Enlasia Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Enlasia Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AAFCE1278E1ZV | Haryana | Active | 29 Nov 2019 |
To see the full GST registrations and return filing status of Enlasia Pharmaceuticals Private Limited, buy the company report.
Recent activity
Enlasia Pharmaceuticals Private Limited has 2 board changes on record since 2018: 2 appointments. The latest: Chhaya Bhatnagar was appointed as Director on 30 Jul 2018.
Frequently asked questions
Enlasia Pharmaceuticals has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Enlasia Pharmaceuticals was a private limited company based in Gurugram, Haryana, India. The company worked in specialty, within the trading industry. It was incorporated on 30 July 2018 and is registered under CIN U51909HR2018PTC075143. The company has been struck off by the Registrar of Companies and is no longer operational.
Enlasia Pharmaceuticals had 2 directors:
- Rakesh Mittal - Director
- Chhaya Bhatnagar - Director
The CIN (Corporate Identification Number) of Enlasia Pharmaceuticals is U51909HR2018PTC075143. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Enlasia Pharmaceuticals is at Office No. 58117 Nai Basti Gurugram, Haryana, India – 122001.
Enlasia Pharmaceuticals was incorporated on 30 July 2018. It is registered with the Registrar of Companies, Delhi.
The latest financial statements of Enlasia Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2019 are in the company report.
The GSTIN of Enlasia Pharmaceuticals is 06AAFCE1278E1ZV, registered in Haryana.
Enlasia Pharmaceuticals operated in the trading industry, in the specialty segment. It worked in this industry before it was struck off.
The peers of Enlasia Pharmaceuticals by revenue are Omkam Pharmaceuticals Private Limited, Kokban Ayurvedic Pharmaceuticals Private Limited, Ocecure Pharmaceuticals Private Limited, Cipa Pharmaceuticals Private Limited, Logyesthesia Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Chhaya Bhatnagar was appointed as Director on 30 Jul 2018. Rakesh Mittal was appointed as Director on 30 Jul 2018.

